The U.S. Department of Commerce reported a sharp decline in exports to Russia since the start of the Ukraine conflict, with an 86% drop recorded in the early period of the campaign. The report was summarized by TASS, citing U.S. Deputy Secretary of Commerce Thea Roseman-Kandler.
From February 2022 through September 2023, the value of all U.S. goods shipped to Russia decreased by 86%, amounting to a loss of roughly $7.4 billion. The post-cutback trade that remains is mainly in medical products, including vaccines, according to Roseman-Kandler during testimony before the U.S. House Foreign Affairs Committee.
On the whole, global exports to Russia declined by about 24%, totaling around $87.4 billion, Roseman-Kandler noted. This drop affected a wide range of electronics produced in the United States and other allied nations. Concurrently, the United States continues to seek ways to curb the parallel importation of sanctioned goods and to deter secondary trade channels that bypass official controls.
In general terms, U.S. pharmaceutical supplies and related products remain part of the ongoing shipments to Russia, reflecting a carefully managed balance between public health needs and sanctions enforcement.
Earlier, officials from the Ministry of Industry and Trade of Russia outlined changes impacting the country’s drug market, offering context for ongoing shifts in supply and pricing dynamics.
Nikolai Patrushev, a former secretary of the Russian Security Council, commented on the drawbacks associated with parallel imports, highlighting concerns about regulatory oversight and market stability.